

J Harvey Turner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4911475/publications.pdf>

Version: 2024-02-01

35
papers

1,176
citations

567281

15
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

1221
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 237-241.	2.5	6
2	Myeloid Toxicity of Radionuclide Cancer Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 164-172.	1.0	2
3	Ethics of Pharma Clinical Trials in the Era of Precision Oncology. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 1-9.	1.0	5
4	Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients. <i>Diagnostics</i> , 2021, 11, 515.	2.6	8
5	Prospect of Cure in Cancer Care. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 231-236.	1.0	1
6	Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET. <i>Endocrine-Related Cancer</i> , 2021, 28, 521-527.	3.1	14
7	Responsible Radionuclide Cancer Care. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 617-623.	1.0	2
8	Life-Saving Cancer Care. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 711-719.	1.0	1
9	Real-World Evidence of Clinical Outcomes in Precision Radionuclide Oncology: The NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 3799-3803.	1.9	6
10	Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 135-140.	1.0	14
11	Recent advances in theranostics and challenges for the future. <i>British Journal of Radiology</i> , 2018, 91, 20170893.	2.2	60
12	An introduction to the clinical practice of theranostics in oncology. <i>British Journal of Radiology</i> , 2018, 91, 20180440.	2.2	47
13	Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 16.	2.6	90
14	Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 274-281.	1.0	22
15	Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. <i>Diagnostics</i> , 2017, 7, 26.	2.6	7
16	Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2016, 31, 189-198.	1.0	49
17	Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination ¹⁷⁷ Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy. <i>Neuroendocrinology</i> , 2016, 103, 432-439.	2.5	87
18	NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 261-269.	1.0	80

#	ARTICLE	IF	CITATIONS
19	Phase II study of first-line ¹³¹ I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic ¹⁸ F-fluorodeoxyglucose positron emission tomography. <i>Leukemia and Lymphoma</i> , 2015, 56, 1271-1277.	1.3	22
20	Phase III Study of Radiopeptide ¹⁷⁷ Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 561-569.	1.0	144
21	Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 525-529.	1.0	3
22	Outpatient therapeutic nuclear oncology. <i>Annals of Nuclear Medicine</i> , 2012, 26, 289-297.	2.2	26
23	Management of fear of radiation exposure in carers of outpatients treated with iodine-131. <i>Annals of Nuclear Medicine</i> , 2012, 26, 508-514.	2.2	8
24	Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with ¹³¹ I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. <i>Blood</i> , 2011, 117, 45-52.	1.4	71
25	Phase II study of radiopeptide ¹⁷⁷ Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 302-311.	6.4	186
26	First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with ¹³¹ I-Rituximab: The INITIAL Study. <i>Blood</i> , 2011, 118, 3719-3719.	1.4	2
27	Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience. <i>Current Pharmaceutical Design</i> , 2009, 15, 966-982.	1.9	12
28	Repeat Treatment with Iodine-131-Rituximab Is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma (NHL) Who Had Previously Responded to This Therapy. <i>Blood</i> , 2007, 110, 3413-3413.	1.4	0
29	Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in ¹³¹ I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 458-469.	6.4	53
30	¹³¹ I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 513-524.	1.0	43
31	Pelvic fractures diagnosed by bone scintigraphy in patients with normal radiographs after a fall. <i>Medical Journal of Australia</i> , 2000, 172, 302-303.	1.7	1
32	Pelvic fractures diagnosed by bone scintigraphy in patients with normal radiographs after a fall. <i>Medical Journal of Australia</i> , 1999, 171, 476-478.	1.7	9
33	Samarium ¹⁵³ EDTMP therapy of disseminated skeletal metastasis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1989, 15, 784-95.	2.1	83
34	Samarium-153 chelate localization in malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1987, 13, 432-438.	2.1	8
35	Localization of ¹¹ C-radiopharmaceuticals in the Greene melanoma of hamsters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1985, 10-10, 392-7.	2.1	4